EUVIMEDEUVIMED entdecken
Crossref

Investigation of novel 4-substituted piperazine–pyrrolo[2,3-d]pyrimidine N-phenylacetamides as MELK-targeted anticancer agents for breast cancer therapy

Shivangi Makwana, Vivek Pandey, Umang Shah, Mohd Imran, Jasleen Kaur, Ruma Sarkar, Adrija Mukherjee, Shirani Punniyamoorthy, Premlata Kumari

Bioorganic Chemistry · 2026

DOI: 10.1016/j.bioorg.2026.110255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Shivangi Makwana und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Sardar Vallabhbhai National Institute of Technology (SVNIT), Surat, Gujarat, India. Hauptthemen laut MEDLINE: Antineoplastic Agents, Breast Neoplasms, Pyrimidines, Pyrroles. Die Arbeit nennt 57 Literaturangaben. Gefördert von: Northern Border University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The study reports design and synthesis of two series of pyrrolo[2,3-d]pyrimidine-N-phenylacetamide derivatives based on 1-(2,3-dichlorophenyl) piperazine (9a-f) and 1-((4-chlorophenyl) (phenyl)methyl) piperazine (10a-f). Compounds were characterized using 1H NMR, 19F NMR, 13C NMR, and HRMS spectral analyses. Post-chemical characterization, UALCAN analysis revealed elevated expression of MELK at both RNA and protein level in breast cancer, hence studies were conducted in MCF-7 cells. Of the two derivatives, piperazine-substituted compounds 9a-f (dichlorophenyl) showed better activity than 10a-f (chlorobenzhydryl) in the MTT assay. 9b and 9d exhibited modest IC50 of 13.84 ± 1.02 μM and 13.5 ± 1.29 μM, respectively, compared to routine drug 5-fluorouracil, which showed an IC50 of 17.77 ± 1.59 μM. However, a series 10a-f exhibited good to moderate to average cytotoxicity. Further analysis revealed both 9b and 9d exert an inhibitory effect by causing cell death, S-phase cell cycle arrest, and inhibiting migratory potential by upregulating E-Cadherin and downregulating the MMP-9. Molecular docking with the MELK protein revealed favorable binding to key active-site residues. Additionally, 100 ns molecular dynamics simulations confirmed conformational stability and dynamic behavior stable ligand-protein complex throughout the simulation, further western blotting analysis showed direct action of 9b and 9d on MELK expression with later being more prominent. In silico ADME study predicts that compound 9b demonstrates more favorable pharmacokinetic properties than 9d, including adherence to Lipinski's rule, improved oral absorption, enhanced Caco-2/MDCK permeability, and favorable BBB, skin permeability, and plasma protein binding, suggesting their potential as MELK- targeted leads for anticancer candidates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBreast NeoplasmsPyrimidinesPyrrolesPiperazinesProtein Serine-Threonine KinasesProtein Kinase InhibitorsAcetamidesHumansDrug Screening Assays, AntitumorFemaleStructure-Activity RelationshipCell ProliferationDose-Response Relationship, DrugMolecular StructureMolecular Docking SimulationAnimalsPiperazineApoptosisMCF-7 Cells

Stichwörter der Autor:innen

Apoptosis and S-phase arrestIn silico ADME propertiesIn vitro anticancer activityMolecular docking and MD simulationPyrrolo [2,3-d] pyrimidineSubstituted piperazine

Substanzen

Antineoplastic AgentsPyrimidinesPyrrolesPiperazinesProtein Serine-Threonine KinasesProtein Kinase InhibitorsPiperazineAcetamidesPyrrolo(2,3-d)pyrimidine

Autor:innen und Institutionen

  • Department of Chemistry, Sardar Vallabhbhai National Institute of Technology (SVNIT), Surat, Gujarat, India.
  • Dr. B. R. Ambedkar Center for Biomedical Research, University of Delhi, 110007, India.
  • Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT campus, Changa 388421, Gujarat, India.
  • Center for Health Research, Northern Border University, Arar 73213, Saudi Arabia.
  • B.D. Patel Institute of Paramedical Sciences, Charotar University of Science and Technology, CHARUSAT campus, Changa 388421, Gujarat, India.
  • Faculty of Life Sciences and Biotechnology, South Asian University, Maidan Garhi Rajpur Khurd Rd, Maidan Garhi, Delhi 110068, New Delhi, India.

Förderung

  • Northern Border University

Zitieren

APA

Makwana, S., Pandey, V., Shah, U., Imran, M., Kaur, J., Sarkar, R., Mukherjee, A., Punniyamoorthy, S., & Kumari, P. (2026). Investigation of novel 4-substituted piperazine–pyrrolo[2,3-d]pyrimidine N-phenylacetamides as MELK-targeted anticancer agents for breast cancer therapy. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.110255

Vancouver

Makwana S, Pandey V, Shah U, Imran M, Kaur J, Sarkar R, et al. Investigation of novel 4-substituted piperazine–pyrrolo[2,3-d]pyrimidine N-phenylacetamides as MELK-targeted anticancer agents for breast cancer therapy. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.110255

BibTeX
@article{Makwana2026,
  author = {Makwana, Shivangi and Pandey, Vivek and Shah, Umang and Imran, Mohd and Kaur, Jasleen and Sarkar, Ruma and Mukherjee, Adrija and Punniyamoorthy, Shirani and Kumari, Premlata},
  title = {Investigation of novel 4-substituted piperazine–pyrrolo[2,3-d]pyrimidine N-phenylacetamides as MELK-targeted anticancer agents for breast cancer therapy},
  journal = {Bioorganic Chemistry},
  year = {2026},
  doi = {10.1016/j.bioorg.2026.110255}
}
Kostenlos starten →